The company implements the recent prevention and control of the new crown epidemic.
Release time:
2022-12-22
On December 12, the Group held a meeting on the prevention and control of the new coronary pneumonia epidemic, according to the new situation and new characteristics of the domestic epidemic after the adjustment of the epidemic prevention and control policy, combined with the actual situation of the company, to make arrangements for the prevention and control of the recent epidemic. On the 19th, the Group issued a notice to put forward specific requirements for the implementation of epidemic prevention and control measures by its subordinate units.
Since December, the new coronary pneumonia epidemic prevention and control "twenty" "new ten" have been introduced, around the epidemic prevention and management policies have been comprehensively adjusted. At the epidemic prevention and control work meeting on the 12th, Yu Jianhong, general manager of the group company, pointed out that the optimization and adjustment of the national epidemic prevention and control management policy was carefully made based on factors such as the current epidemic characteristics, social and economic development and public demands, but "liberalization" It is not "laissez-faire". The implementation of the new epidemic prevention policy will inevitably cause enterprises to face unprecedented new problems in epidemic prevention and control. All units of the company should make scientific judgments, for possible new situations, make preparations in advance so as to deal with them in a timely and effective manner. Yu Jianhong stressed that the epidemic prevention policy has changed, and the risk of the spread of new crown pneumonia and the threat to personal health have not changed. To effectively prevent infection, we must first establish the awareness that "everyone is the first person responsible for their own health". All employees should further strengthen personal protection and family protection, and maintain good living and hygiene habits. Enterprises should make emergency plans in advance according to different situations that may arise, prepare necessary epidemic prevention facilities and materials, and strengthen internal epidemic prevention knowledge propaganda to prevent the rapid spread of the epidemic. At the end of the year, the production and operation of the enterprise has entered the final sprint stage. Yu Jianhong hopes that all units will fully consider the possible impact of the "post-epidemic" on the work quality and safety of enterprises. On the one hand, they should do a good job in production organization, encourage energy, seize time and grasp the market, make up for the losses caused by the epidemic as much as possible, draw a more satisfactory end to the work of the whole year, and on the other hand, firmly implement the epidemic prevention and control management to provide protection for the health and safety of production organizations and employees.
At this meeting, Xiang Chongping, deputy general manager of the group company, analyzed the epidemic situation under the new policy and made arrangements for the key work of the recent enterprise epidemic prevention and control management. In view of the new situation that may be brought about by the new policy, the company requires all units to further establish and improve the internal epidemic prevention and control system, do not engage in "layer by layer", scientifically formulate emergency plans, strengthen epidemic prevention publicity, and implement various prevention and control measures with the attitude of "responsibility in place, responsibility to people"; prepare epidemic prevention materials in advance, do daily killing in public areas, and do psychological counseling for employees; actively respond to and strictly implement the "all people wear masks" initiative, advocate as little as possible in addition to work, less gathering, in response to the spread of the epidemic may lead to labor shortages, in advance to do a good job of human resources allocation emergency plan, to ensure the normal development of production and operation. After the meeting, all units of the company implemented various tasks in accordance with the spirit of the meeting and the requirements of epidemic prevention and control in the location of the enterprise. On the 19th, according to the new situation of the rapid increase in the number of new crown pneumonia infections in society, the company issued a notice, on the workplace access, epidemic prevention materials preparation, workplace killing, reasonable arrangements for personnel, canteen meal management and other recent epidemic prevention and control work focus on specific requirements. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page